1. Record Nr. UNINA9910450500603321

Titolo	The textbook of pharmaceutical medicine [[electronic resource]]
Pubbl/distr/stampa	London, : BMJ Books, 2002
ISBN	1-280-19787-0 9786610197873 1-4051-4606-0 1-4237-1777-5
Edizione	[4th ed. /]
Descrizione fisica	1 online resource (896 p.)
Altri autori (Persone)	GriffinJ. P (John Parry) O'GradyJohn
Disciplina	615.1
Soggetti	Pharmaceutical chemistry Pharmacology Electronic books.
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Includes index. Previous ed.: / edited by J.P. Griffin, J. O'Grady, P.F. D'Arcy. Belfast : Queen's University of Belfast, c1998.
Nota di contenuto	Contents; Contributors; Preface; Acknowledgements; The editors; 1: Discovery of new medicines; 2: Pharmaceutical development; 3: Toxicity testing; 4: Exploratory development; 5: Clinical pharmacokinetics; 6: Clinical trials and good clinical practice; 7: Medical statistics; 8: Development of medicines: full development; 9: The medical department; 10: Medical marketing; 11: Information and promotion; 12: The supply of unlicensed medicines for particular patient use; 13: Legal and ethical issues relating to medicinal products; 14: The safety of medicines 15: The development of the control of human medicines in Europe from classical times to the year 200016: Technical requirements for registration of pharmaceuticals for human use: the ICH process and the common technical document; 17: The regulation of drug products by the United States Food and Drug Administration; 18: The US FDA in the drug development, evaluation and approval process; 19: Regulatory and clinical trial systems in Japan; 20: Economics of healthcare; 21:

	Controls on NHS medicines prescribing and expenditure in the UK (a historical perspective); Appendix 1; Appendix 2 PRESCRIPTION MEDICINES CODE OF PRACTICE AUTHORITY Constitution and ProcedureIndex
Sommario/riassunto	This edition has totally revised chapters on drug regulation in the USA, with new contributor, Dr Peter Barton Hutt formerly FDA Special Counsel. New contributions regarding pharmaco-economics are covered in two new chapters.